MiMedx Group, Inc
MiMedx develops placental tissue allografts for various healthcare sectors. The company uses its patented PURION process to retain biological properties and regulatory proteins. Products include EpiFix, AmnioFix, EpiCord, and AmnioCord for wound care, burn, and surgical recovery. These products are sold through direct sales force, independent agents, and distributors in the US. MiMedx was incorporated in 2011 and is headquartered in Marietta, Georgia. The company processes placental tissues using aseptic techniques and terminal sterilization. Its products have applications in wound care, burn, and surgical sectors of healthcare.
Overview
Strengths
- Pricing power: gross margin has held between 82% and 84% over the last 6 years (latest 82.6%).
- Our discounted cash flow model points to 50% upside (target price 4.94 USD), and even our pessimistic growth scenario implies 35%: a margin of safety.
- High-quality earnings: over the last 6 years, free cash flow added up to 180% of reported net income.
- Valued below its Biotechnology peers: P/E 10.0x vs. a median of 20.4x, P/FCF 6.7x vs. a median of 20.2x and EV/EBITDA 4.3x vs. a median of 15.6x.
- Consistent growth: revenue has compounded at 11.0% a year over 5 years, rising in 4 of them.
- ROIC of 27.0% beats 82% of its 128 Biotechnology peers (median 0.0%).
Weaknesses
- Unreliable cash generation: free cash flow was negative in 3 of the last 6 years.
- Unstable profitability: operating margin ranged from -18% to 17% over the last 6 years, with operating losses in 3 of them.
- Shareholder dilution: the share count has grown by 9.2% a year over the last three years.
- Earnings are projected to decline (-4.8% per year).
- Deteriorating fundamentals over the last year: return on assets down 1.9 points and asset turnover down 7.6%.
Key Financial Data